Deescalating Adjuvant Trastuzumab in HER2-Positive Early-Stage Breast Cancer: A Systemic Review and Meta-Analysis.

Hadar GoldvaserYasmin KorzetsDaniel ShepshelovichRinat YerushalmiMichal SarfatyDomen RibnikarPaaladinesh ThavendiranathanEitan Amir

Published in: JNCI cancer spectrum (2019)

Compared with 1 year, shorter duration of adjuvant trastuzumab is associated with statistically significantly worse DFS and OS despite favorable cardiotoxicity profile. One year of targeted HER2 treatment should remain the standard adjuvant treatment in early-stage HER2-positive disease with appropriate cardiac monitoring.

Keyphrases

early stage
sentinel lymph node
epidermal growth factor receptor
heart failure
combination therapy
drug delivery
lymph node
young adults